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Epidemiological studies have shown the protective effect of KIR3DL1/HLA-Bw4 genotypes in human immunodeficiency virus type 1 (HIV-1) infection; however, the functional correlates for the protective effect remain
unknown. We investigated whether human leukocyte antigen (HLA)-Bw4-presented HIV-1 peptides could affect
the interaction between the inhibitory natural killer (NK) cell receptor KIR3DL1 and its ligand HLA-Bw4.
Distinct HIV-1 epitopes differentially modulated the binding of KIR3DL1 to HLA-Bw4. Furthermore, cytotoxic
T lymphocyte (CTL) escape mutations within the immunodominant HLA-B57 (Bw4)-restricted Gag epitope
TSTLQEQIGW abrogated KIR3DL1 binding to HLA-B57, suggesting that sensing of CTL escape variants by
NK cells can contribute to the protective effect of the KIR3DL1/HLA-Bw4 compound genotype.
infection preferentially in individuals that express HLA-Bw480I (2).
The combination of certain alleles of the inhibitory receptor
KIR3DL1 and HLA-Bw4 has also been shown to be protective
in HIV-1 infection (13). KIR3DL1 is highly polymorphic, and
different allotypes result in different expression levels of
KIR3DL1 on the cell surface of NK cells. A genetic study on a
large cohort of HIV-1-infected individuals showed that individuals expressing KIR3DL1 allotypes that result in high levels
of KIR3DL1 expression (KIR3DL1hi), in conjunction with
HLA-Bw4-80I, have significantly slower HIV-1 disease progression than individuals who express KIR3DL1 allotypes resulting in low levels of KIR3DL1 expression (KIR3DL1lo), and
that KIR3DL1hi strongly enhances protection conferred by
HLA-Bw4-80I alleles alone (13). The functional correlates for
the protective effect of the KIR3DL1hi/HLA-Bw4-80I genotype in HIV-1 infection are not understood.
Several functional studies suggest that the interaction between KIR and cognate HLA class I can be modulated by the
HLA-presented peptide (15) and that in particular amino acid
residues 7 and 8 of the HLA-bound peptide can promote or
prevent KIR interaction (15, 17). This was further supported
by the resolution of the crystal structures of KIR2D receptors
with HLA class I showing that KIR binds the ␣1 and ␣2 helix
of major histocompatibility complex (MHC) class I and makes
contact with the C-terminal end of the bound peptide (3).
These structural and functional data suggest that changes in
the HIV-1 epitopes presented by HLA class I during HIV-1
infection may affect KIR-HLA interactions and provide a potential mechanism for the protective effect of the KIR3DL1hi/
HLA-Bw4 genotype in HIV-1 infection.
We therefore investigated whether the common KIR3DL1hi
allotype KIR3DL1*001 could discriminate between different
HIV-1 epitopes presented by HLA-Bw4 molecules and show
that different HIV-1 peptide variants can significantly modulate binding between KIR3DL1*001 and different HLA-Bw4/

Epidemiological studies have demonstrated the strong influence of human leukocyte antigen (HLA) class I genes on the
outcome of human immunodeficiency virus type 1 (HIV-1)
infection (7). Control of HIV replication and slower disease
progression are associated with HLA-B alleles expressing the
serological Bw4 motif (HLA-Bw4) (10), which include HLAB57 and HLA-B27. HLA-Bw4 molecules are ligands for receptors on T cells and natural killer (NK) cells and therefore
can modulate both innate and adaptive immune responses.
CD8⫹ T cells recognize HLA class I-presented viral peptides
through the T cell receptor (TCR) and are central for control
of HIV-1 infection. It is now well established that HIV-1 can
evade cytotoxic T lymphocyte (CTL)-mediated immune pressure through the selection of escape mutations within HLA
class I-presented epitopes. In addition, HLA class I molecules
also serve as ligands for the killer immunoglobulin-like receptors (KIRs), a family of receptors expressed on NK cells and T
cells.
The role of KIR-HLA interactions in HIV-1 infection has
received increasing attention over recent years. A significant
association between slower HIV-1 disease progression and expression of the NK cell-activating receptor KIR3DS1 in conjunction with its putative ligand, HLA-Bw4 molecules that
express isoleucine at position 80 (HLA-Bw4-80I), described
the first association between NK cell receptors and HLA in
modulating the clinical outcome of HIV infection (12). Although direct interaction between KIR3DS1 and HLA-Bw480I has not been demonstrated, NK cells expressing KIR3DS1
control HIV-1 replication in HLA-Bw4-80I-expressing target
cells (1), and KIR3DS1⫹ NK cells expand in acute HIV-1
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peptide tetramers. Furthermore, point mutations that are frequently selected by CD8⫹ T cells within a dominant HLA-B57restricted HIV-1 epitope in Gag abrogated binding of the
inhibitory NK cell receptor KIR3DL1*001 to HLA-B*5701,
suggesting that combined CTL- and NK cell-mediated immune
pressure can contribute to the described protective effect of the
KIR3DL1hi/HLA-Bw4 compound genotype.
MATERIALS AND METHODS
Cell lines. Jurkat cells transfected with KIR3DL1*001-GFP (green fluorescent
protein) were generated as previously described (14). Cells were cultured and
maintained in growth medium (R10) containing RPMI medium 1640 (Gibco)
supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% penicillinstreptomycin (Sigma-Aldrich), and 2 mM L-glutamine (Sigma-Aldrich) at 37°C
under 5% CO2. Cells were cultured in 1 mg/ml G418 selection (Sigma-Aldrich)
and maintained in logarithmic phase at neutral pH by diluting the cultures at a
1:10 dilution every 72 h.
Tetramer staining. KIR3DL1*001 Jurkat cells were stained with a panel of
HLA class I tetramers refolded with HIV-1 peptides, including HLA-Bw4
tetramers (HLA-B*5701, HLA-B*2705, and HLA-A*2402) and HLA-Bw6 tetramers (HLA-B*08) as negative controls. Tetramer staining was verified using
specific CTL clones (data not shown). Cells (2 ⫻ 105) were washed and resuspended in 100 l wash buffer (phosphate-buffered saline [PBS] containing 1%
FCS). Two microliters of phycoerythrin (PE)- or allophycocyanin (APC)-conjugated tetramers (Beckman Coulter) was added to KIR3DL1*001 Jurkat cells for
30 min at room temperature. Cells were washed and fixed in 1% paraformaldahyde until flow cytometric analysis was performed (FACSCanto; BD).
Statistical analysis. All experiments represent the means of results from five
separate experiments. Unpaired t tests were used to determine statistical significance of differences. P values of ⬍0.05 were considered significant.

RESULTS
Previous studies have shown that KIR3DL1 allotypes differ
in their ability to bind HLA-Bw4 tetramers refolded with viral
peptides (17). We investigated the ability of KIR3DL1*001, a
KIR3DL1 allotype associated with slower disease progression
in HIV-1 infection, to bind to different fluorescently labeled
HLA-B tetramers refolded with HIV-1 peptides. KIR3DL1
binds HLA-B alleles with the serologically defined Bw4
epitope representing approximately 40% of HLA-B alleles.
The remainder of HLA-B alleles carries the Bw6 motif (HLABw6) and do not serve as ligands for KIR3DL1.
In accordance with the HLA-Bw4 allelic specificity of
KIR3DL1, Jurkat cells transfected with KIR3DL1*001 bound
HLA-Bw4 (HLA-B*5701, HLA-B*2705, and HLA-A*2402)
but not HLA-Bw6 (HLA-B*0801) tetramers (Fig. 1a and b).
Furthermore, the interaction between KIR3DL1*001 and the
same HLA-Bw4 allele was influenced by different peptides
(Fig. 1a and b). Strong binding of KIR3DL1*001 to HLAB*5701 in the presence of some epitopes, including the
Gag147-158 ISPRTLNAW epitope and Gag240-249 TSTLQE
QIGW (TW10), was observed; however, HLA-B*5701 tetramers refolded with the Gag162-172 KAFSPEVIPMF epitope
bound weakly to KIR3DL1*001. The interaction between
KIR3DL1 and HLA-B*2705 has been shown to be most sensitive to amino acid substitutions at positions 7 and 8 of a
nonamer peptide (15), and charged residues at these positions
are present in peptides that do not protect against lysis by
KIR3DL1⫹ NK cells. In line with this data, binding of
KIR3DL1*001 to HLA-B*5701 was abrogated by the
RT244-252 IVLPEKDSW epitope (P ⬍ 0.0001; compared to
binding of HLA-B*5701: TSTLQEQIGW to KIR3DL1*001),

5971

which carries a negatively charged aspartic acid residue at
position 7. HLA-A*2402 carries the HLA-Bw4 motif and has
been shown to bind KIR3DL1 (17). Binding of HLA-A*2402
tetramers to KIR3DL1*001 was also influenced by the presented peptide; HLA-A*2402:Gag162-172 RDYVDRFFKTL
bound strongly to KIR3DL1*001, while weaker binding of
HLA-A*2402:Gag28-36 KYRLKHIVW to KIR3DL1*001 was
observed (P ⬍ 0.0001). These data demonstrate that the inhibitory NK cell receptor KIR3DL1 can discriminate between
different HIV peptides presented by HLA-Bw4 molecules.
The immunodominant Gag240-249TW10 epitope is one of the
first HIV-1 epitopes targeted by CD8⫹ T cells in HLA-B*57⫹
individuals during acute HIV-1 infection and one of the first
epitopes to escape from CD8⫹ T cell-mediated immune pressure (6, 11). Despite this escape from CTL-mediated immune
pressure, HLA-B*57⫹ individuals, and in particular those that
coencode KIR3DL1hi, are highly enriched in cohorts of individuals with well-controlled HIV-1 infection (13). We investigated whether CTL escape mutations in the TW10 epitope at
well-described positions of variation could affect the interaction between KIR3DL1*001 and HLA-B*5701 (Fig. 2a and b).
KIR3DL1*001 bound strongly to the wild-type TSTLQE
QIGW epitope; however, binding to HLA-B*5701 was significantly abrogated by the T242N mutation (TSNTLQEQIGW;
bold letters indicate changes from the wild-type epitope) (P ⬍
0.0001; compared to binding of HLA-B*5701: TSTLQEQIGW
to KIR3DL1*001). KIR3DL1*001 binding to HLA-B*5701
was also significantly abrogated in the presence of two additional TW10 peptide variants that arise in HLA-B57⫹ individuals: TSNLQEQIAW and TSTLQEQIDW (P ⬍ 0.0001; compared to binding of HLA-B*5701: TSTLQEQIGW to
KIR3DL1*001). Thus, sequence mutations within the TW10
epitope that have been shown to be selected by CD8⫹ T cells
and that abrogate CD8⫹ T cell recognition also reduce the
binding of the inhibitory NK cell receptor KIR3DL1, potentially resulting in disinhibition of NK cells and rendering infected cells susceptible to NK cell lysis.
DISCUSSION
We have shown that binding of KIR3DL1*001, a KIR3DL1
allotype that results in high protein surface expression of
KIR3DL1, to HLA-Bw4 molecules is modulated by the HLApresented HIV-1 peptide. Binding of HLA-B*5701 to
KIR3DL1*001 was promoted by Gag147-158 ISPRTLNAW and
Gag240-249 TSTLQEQIGW peptides; however, weak binding
and abrogation of binding was detected when HLA-B*5701
tetramers were refolded with Gag162-172 KAFSPEVIPMF and
RT244-252 IVLPEKDSW, respectively. These data show that
HIV-1 peptides can promote or prevent binding of HLA molecules to a specific KIR3DL1 molecule. HIV-1 peptides that
abrogate inhibitory KIR-HLA interactions may promote recognition of an infected target cell in vivo, while HIV-1 peptides
that induce strong inhibitory KIR-HLA interactions may allow
escape from NK cell recognition and represent an immune
evasion strategy for the virus, as recently suggested in the
simian immunodeficiency virus (SIV) model (8). It has been
shown that KIR⫹ NK cells are activated more readily in response to peptide repertoire changes than to MHC class I
downregulation (9). In this study, only a small peptide rep-

FIG. 1. Peptide-dependent binding of HLA class I tetramers to KIR3DL1*001. (a and b) Jurkat cells transfected with KIR3DL1*001-GFP were
stained with HLA-Bw4 (HLA-B*5701, HLA-B*2705, and HLA-A*2402) or HLA-Bw6 (HLA-B*08) fluorescently labeled tetramers refolded with
HIV-1 peptides. Tetramer binding was assessed by flow cytometry. (a) Representative flow-cytometric dot plots with percentages of tetramerpositive cells are shown. (b) Percentages of tetramer-positive KIR3DL1*001⫹ Jurkat cells are shown ⫾standard errors of the means (SEM) and
are representative of results from five separate experiments. Statistically significant results are denoted by an asterisk (unpaired two-tailed t test).
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FIG. 2. Naturally occurring CTL escape mutations in TW10 epitope abrogate KIR3DL1*001 binding to HLA-B*5701. (a) Jurkat cells
transfected with KIR3DL1*001-GFP were stained with HLA*B8: FLKEKGGL, HLA-B*5701 tetramers refolded with Gag240-249 wild-type peptide
TSTLQEQIGW, or mutant peptides (TSNTLQEQIGW, TSNTLQEQIAW, or TSTLQEQIDW). Tetramer binding was assessed by flow cytometry. (b) Percentages of tetramer-positive KIR3DL1*001⫹ Jurkat cells are shown ⫾SEM and are representative of results from five separate
experiments. Statistically significant results are denoted by an asterisk (unpaired two-tailed t test).

ertoire change toward peptides that are nonpermissive for
KIR binding resulted in KIR⫹ NK cell activation (9). Therefore, KIR3DL1hi NK cells may respond strongly to small
changes in peptide repertoire during HIV-1 infection if
these peptides are nonpermissive for KIR binding, even in
the presence of other virus- or host-derived peptides that do
not interrupt KIR binding.
HIV-1 adaptation through amino acid point mutations to
evade adaptive immune responses has been well described.
The immunodominant HLA-B57-restricted Gag240-249 TSTLQ
EQIGW (TW10) epitope is targeted early in acute infection
(16) but rapidly escapes in HLA-B57⫹ individuals (6). The
dominant sequence substitution is TSNLQEQIGW and is often associated with a further substitution at position 248, TSN
LQEQIAW (11). Other mutations have been shown to arise in
the TW10 epitope, including Gag240-249 TSTLQEQIDW. We
showed that while KIR3DL1*001 can bind to HLA-B*5701 in

the presence of the wild-type TW10 peptide, this interaction is
significantly reduced in the presence of all three TW10 mutants tested (TSNLQEQIGW, TSNLQEQIAW, and TSTLQE
QIDW). Our observations that peptide changes within T cell
epitopes can impact KIR3DL1 binding to HLA-B*5701 is in
line with a recent study describing the consequences of sequence changes within HLA-B*5703-presented epitopes for
KIR3DL1*002 binding (4), and further investigation into the
functional implications of these modulations of KIR-HLA interactions is now required. Previous studies on KIR interaction
with HLA have indicated that KIR binds the HLA-bound
peptide at the C-terminal end (3, 15), and the change from a
glutamine (G) to an alanine (A) or aspartic acid (D) in amino
acid position 9 of the TW10 epitope may therefore prevent
KIR interaction with HLA. The point mutation at position 242
of TW10 (TSNLQEQIGW) lies at the N-terminal end of the
epitope, and how this peptide abrogates KIR recognition re-
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quires further investigation. One explanation is that a point
mutation at this N-terminal position may induce a change in
the overall tertiary structure of the peptide affecting KIR binding at the C-terminal residues.
The TW10 epitope escapes rapidly in HLA-B*57⫹ individuals, though control of viremia in many of these individuals still
persists. This has been suggested to be due to a reduction in
viral fitness following escape (11), but in vitro data indicate that
the reduction in viral fitness is minimal (5). In the context of
the data presented here, it is possible that recognition of HLAB*5701 by the inhibitory KIR3DL1hi is lost in the presence of
the TW10 escape mutations, resulting in activation of
KIR3DL1⫹ NK cells and control of viremia. This model is
consistent with the epidemiological data showing that individuals expressing HLA-B*57 and KIR3DL1hi have slower disease progression than individuals expressing HLA-B*57 in the
absence of KIR3DL1. In summary, these data provide novel
insights into the potential mechanisms underlying the slower
HIV-1 disease progression associated with the KIR3DL1hi/
HLA-B57 compound genotype.
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